Association Between C-Reactive Protein to Albumin Ratio and Left Ventricular Thrombus Formation Following Acute Anterior Myocardial Infarction

Cirakoglu O. F. , Aslan A. O. , YILMAZ A. S. , Sahin S., Akyuz A. R.

ANGIOLOGY, vol.71, no.9, pp.804-811, 2020 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 71 Issue: 9
  • Publication Date: 2020
  • Doi Number: 10.1177/0003319720933431
  • Journal Name: ANGIOLOGY
  • Journal Indexes: Science Citation Index Expanded, Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, CINAHL, EMBASE, MEDLINE
  • Page Numbers: pp.804-811
  • Keywords: C-reactive protein to albumin ratio, inflammation, left ventricular thrombus, anterior myocardial infarction, 2013 ACCF/AHA GUIDELINE, CARDIOVASCULAR-DISEASE, UNIVERSAL DEFINITION, TASK-FORCE, ELEVATION, INFLAMMATION, MANAGEMENT, ECHOCARDIOGRAPHY, ERA


Left ventricular thrombus (LVT) is associated with inflammatory response in survivors with anterior ST-elevation myocardial infarction (STEMI). The C-reactive protein to albumin ratio (CAR) has been proposed as a marker of inflammation. However, there is a lack of data with respect to the role of CAR in LVT development. We investigated the relationship between CAR and LVT development in patients with anterior STEMI treated percutaneously; 955 consecutive patients were enrolled and LVT was observed in 126 (13.2%) patients. Clinical, demographic, and laboratory parameters were recorded. The CAR was significantly higher in patients with LVT (12.6 [8.6-16.1] vs 18.1 [11.5-23],P< .001). Other independent predictors for LVT development were lower ejection fraction, the presence of left ventricular apical aneurysm, proximal left anterior descending lesion location, glycoprotein IIb/IIIa inhibitors treatment, >1 diseased arteries, higher total protein level, neutrophil count, and peak creatine kinase myocardial band activity. In conclusion, the CAR may be useful as a simple tool for predicting LVT development among survivors of anterior STEMI.